Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 24, Number 4—April 2018

Research

Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017

Mai-Juan Ma1, Cheng Liu1, Meng-Na Wu, Teng Zhao, Guo-Lin Wang, Yang Yang, Hong-Jing Gu, Peng-Wei Cui, Yuan-Yuan Pang, Ya-Yun Tan, Hui Hang, Bao Lin, Jiang-Chun Qin, Li-Qun FangComments to Author , Wu-Chun CaoComments to Author , and Li-Ling ChengComments to Author 
Author affiliations: Beijing Institute of Microbiology and Epidemiology, Beijing, China (M.-J. Ma, M.-N. Wu, T. Zhao, G.-L. Wang, H.-J. Gu, L.-Q. Fang, W.-C. Cao); University of Florida, Gainesville, Florida, USA (Y. Yang); Suzhou Municipal Center for Disease Control and Prevention, Suzhou, China (C. Liu, P.-W. Cui, Y.-Y. Pang, Y.-Y. Tan, H. Hang, B. Lin, J.-C. Qin, L.-L. Chen)

Main Article

Table 2

Underlying disease, complications, and treatment of influenza A(H7N9) virus survivors, China, 2017*

Patient no. Underlying disease Complications Oxygen therapy Mechanical ventilation Days to antiviral treatment† Oseltamivir Glucocorticoid
1 HTN, DM ARDS, RF Yes No 6 Yes Yes
2 No ARDS, RF Yes No 13 Yes Yes
3 No ARDS, RF Yes No 8 Yes Yes
4 COPD, HTN No Yes No 6 Yes Yes
5 HTN ARDS, RF Yes No 7 Yes Yes
6 HTN, DM ARDS, HI Yes No 14 Yes No
7 No ARDS Yes No 9 Yes Yes
8 No No Yes No 7 Yes Yes
9 No No Yes No 9 Yes Yes
10 No ARDS, RF, HI, RI Yes Yes 11 Yes Yes
11 No HI Yes No 7 Yes Yes
12 No No Yes No 8 Yes No
13 No No Yes No 8 Yes Yes
14 No No Yes No 6 Yes Yes
15 No HI Yes No 7 Yes Yes
16 No RF Yes No 13 Yes No
17 No ARDS Yes No 9 Yes Yes
18 No No Yes No 13 Yes Yes
19 No RF, HI Yes No 5 Yes Yes
20 HTN ARDS, RF, HI Yes Yes 11 Yes Yes
21 HTN, DM, HL ARDS, RF, HI Yes Yes 5 Yes Yes
22 HTN ARDS, RF, HI Yes No 7 Yes Yes
23 HTN No Yes No 6 Yes NA
24 NA NA Yes NA 1 Yes NA
25 CHB HI Yes No 9 Yes Yes

*ARDS, acute respiratory distress syndrome; CB, chronic bronchitis; CHB, chronic hepatitis B infection; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HI, hepatic insufficiency; HL, hyperlipidemia; HTN, hypertension; NA, not available; RF, respiratory failure; RI, renal insufficiency.
†After admission.

Main Article

1These authors contributed equally to this article.

Page created: June 22, 2018
Page updated: June 22, 2018
Page reviewed: June 22, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external